Show simple item record

dc.creatorPerović, I.
dc.creatorMilovanović, M.
dc.creatorStanić, Dragana
dc.creatorBurazer, Lidija
dc.creatorPetrović, D.
dc.creatorMilčić-Matić, Natalija
dc.creatorGafvelink, G.
dc.creatorvan Hage, M.
dc.creatorJankov, R.
dc.creatorĆirković-Veličković, Tanja
dc.date.accessioned2020-06-03T13:15:06Z
dc.date.available2020-06-03T13:15:06Z
dc.date.issued2009
dc.identifier.issn0954-7894
dc.identifier.urihttp://vet-erinar.vet.bg.ac.rs/handle/123456789/621
dc.description.abstractTreating allergies with modified allergens is an approach to make the treatment safer and more efficient. Art v 1 is the most prominent allergen of mugwort pollen and a significant cause of hayfever around Europe. The aim of this study was to reduce the allergenicity of Art v 1 by acetylation, and to investigate the capacity of the modified protein to generate blocking antibodies. The reduction of allergenicity of Art v 1 following acetylation was monitored by immunoblot, ELISA inhibition using a pool of sera from mugwort pollen allergic patients, basophil activation assay and by skin prick testing of mugwort-allergic patients. Rabbits were immunized against Art v 1 and acetylated Art v 1 (acArt v 1) and the rabbit antisera were tested for their capacity to block human IgE binding in ELISA. Human T cell proliferation against Art v 1 and acArt v 1 was examined in peripheral blood mononuclear cells (PBMCs) of mugwort pollen allergic patients and cytokine release in PBMC cultures was monitored. Acetylation of Art v 1 gave a derivative of reduced allergenicity in the in vitro and ex vivo tests applied. The skin test reactivity to acArt v 1 was significantly reduced in 19 patients when compared with the reactivity to Art v 1. Rabbit antibodies to acArt v 1 and Art v 1 showed similar capacity to block human IgE binding to Art v 1 in inhibition ELISA. Both proteins were able to induce proliferation of PBMCs and CD3/CD4(+) cells of mugwort-allergic patients. Release of IL-5 was significantly reduced in cultures stimulated with acArt v 1. Art v 1 modified by acetylation had a significantly reduced allergenicity in vitro and in vivo, while its immunogenicity was retained. Modification of allergens by acetylation could be a new strategy for allergen-specific immunotherapy. Cite this as: I. Perovic, M. Milovanovic, D. Stanic, L. Burazer, D. Petrovic, N. Milcic-Matic, G. Gafvelin, M. van Hage, R. Jankov and T. Cirkovic Velickovic, Clinical and Experimental Allergy, 2009 (39) 435-446.en
dc.publisherWiley, Hoboken
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/142020/RS//
dc.rightsrestrictedAccess
dc.sourceClinical and Experimental Allergy
dc.subjectacetylationen
dc.subjectallergen-specific immunotherapyen
dc.subjectallergoiden
dc.subjectArt v 1en
dc.subjectblocking antibodiesen
dc.subjectmugwort pollen allergyen
dc.titleAllergenicity and immunogenicity of the major mugwort pollen allergen Art v 1 chemically modified by acetylationen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractПетровић, Д.; Милчић-Матић, Наталија; Гафвелинк, Г.; Буразер, Лидија; Јанков, Р.; Ћирковић-Величковић, Тања; Станић, Драгана; Миловановић, М.; Перовић, И.; ван Хаге, М.;
dc.citation.volume39
dc.citation.issue3
dc.citation.spage435
dc.citation.epage446
dc.citation.other39(3): 435-446
dc.citation.rankM21
dc.identifier.wos000262879100018
dc.identifier.doi10.1111/j.1365-2222.2008.03158.x
dc.identifier.pmid19178539
dc.identifier.scopus2-s2.0-58849114494
dc.identifier.rcubconv_1631
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record